What the FDA labels say about taking them together
Arformoterol and fluticasone/umeclidinium/vilanterol
Fluticasone/umeclidinium/vilanterol's FDA label of June 2, 2023 names arformoterol in its warnings and precautions section; arformoterol's label does not name fluticasone/umeclidinium/vilanterol itself but warns about its class (Corticosteroids).
Check it at the source: the arformoterol FDA label on DailyMed (effective April 14, 2026, Sun Pharmaceutical Industries, Inc.); the fluticasone/umeclidinium/vilanterol FDA label on DailyMed (effective June 2, 2023, GlaxoSmithKline LLC).
What does the arformoterol label say about fluticasone/umeclidinium/vilanterol?
Arformoterol's label does not name fluticasone/umeclidinium/vilanterol itself; it warns about its class (Corticosteroids):
Arformoterol label, contraindicationsArformoterol tartrate inhalation solution is contraindicated in patients with a history of hypersensitivity to arformoterol, racemic formoterol or to any other components of this product. (4) Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma.
Arformoterol label, warnings and precautionsUse of long-acting beta2-adrenergic agonists (LABA) as monotherapy [without inhaled corticosteroids (ICS)] for asthma is associated with an increased risk of asthma-related death.
Source: FDA drug label (Arformoterol Tartrate), Sun Pharmaceutical Industries, Inc., effective April 14, 2026 (SPL set f1005878-0c48-4b9a-843e-b6cf6b8bb251), via openFDA; the full label on DailyMed
What does the fluticasone/umeclidinium/vilanterol label say about arformoterol?
Fluticasone/umeclidinium/vilanterol label, warnings and precautionsPatients using TRELEGY ELLIPTA should not use another therapy containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason.
Source: FDA drug label (Trelegy Ellipta), GlaxoSmithKline LLC, effective June 2, 2023 (SPL set b5a81d5a-4648-4c7a-951d-33c014a63c7e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Arformoterol | Fluticasone/umeclidinium/vilanterol | |
|---|---|---|
| Labeled for | COPD | COPD, Asthma |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.633 per mL 15 mcg/2 mL solution | $11.12 per unit 100-62.5-25 |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once